bms-599626
Small moleculeexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2004 (NCT00095537)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
EGFR inhibitor
ERBB4 inhibitor
ERBB2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12- Mol. weight
- 530.56 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1645462 ↗
Also known as
- (4-((1-(3-fluorophenyl)methyl)-1h-indazol-5-ylamino)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yl)carbamic acid 3-morpholinylmethyl ester
- ac480
- ac480
- ac-480
- ac-480
- bms599626
- bms 599626
- bms-599626
- bms-599626
- bms-599626
- bms-599626
- bms-599626
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01245543 | Phase 1 | Nov 1, 2010 | Ambit Biosciences, Daiichi Sankyo |
| NCT00979173 | Phase 1 | Nov 1, 2009 | Ambit Biosciences, Duke University |
| NCT00093730 | Phase 1 | Aug 1, 2004 | National Cancer Institute (NCI), University of California, Los Angeles |
| NCT00207012 | Phase 1 | May 1, 2004 | Bristol-Myers Squibb |
| NCT00095537 | Phase 1 | Mar 1, 2004 | Bristol-Myers Squibb |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ambit Biosciences | For profit | 2 | 0 | 1 | 2009 |
| Bristol-Myers Squibb | For profit | 2 | 2 | 1 | 2004 |
| Daiichi Sankyo | For profit | 1 | 1 | 1 | 2010 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2004 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2004 |
6 organizations
Page 1 / 1